Biostem Technologies Inc. (BSEM)
OTC PINK OTC PINK Primary 
BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes
The Company welcomes CMS' efforts to reform skin substitute payment policy and will continue to engage with CMS and other stakeholders to optimize the proposed changes POMPANO BEACH, Fla., July 17, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies to Present at the Advanced Wound Care Summit in Boston on July 15, 2025, at 2:00 PM ET
Jason Matuszewski, Chairman and CEO, to present BioStem's current position in the chronic wound care market and key opportunities for growth POMPANO BEACH, Fla., July 10, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers
Head-to-head study comparing BioREtain®– processed Amnion Chorion (BR-AC) allograft to standard of care initiated in Q4 2024 to demonstrate healing superiority Topline results and full data analysis expected in Q4 2025 Audio Overview – Listened: POMPANO BEACH, Fla., June 23, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
Ernst & Young LLP (EY US) Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award Winner
Award celebrates bold leaders shaping the future through the world's most ground-breaking companies POMPANO BEACH, Fla., June 17, 2025 – PRISM MediaWire – Ernst & Young LLP (EY US) announced that Jason Matuszewski, CEO and Chairman of the Board of BioStem Technologies (OTC: BSEM), was named an Entrepreneur Of The Year 2025 Florida Award winner.
BioStem Technologies: Huge Growth, Poised To Help Wound Care Field
BioStem Technologies is a buy due to strong YoY growth, profitability, and undervaluation versus sector peers despite recent Q1 misses. Their advanced wound care products, powered by proprietary BioREtain technology, address a growing chronic wound market fueled by aging and diabetes trends. Balance sheet strength is notable, with assets outpacing liabilities and a rising cash position, supporting ongoing expansion and innovation.
BioStem Technologies Provides Update on the Company's Form 10 Submission and SEC Review Process
Upon SEC approval of the amended Form 10, BioStem expects to advance its uplisting to Nasdaq POMPANO BEACH, Fla., June 3, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
POMPANO BEACH, Fla., May 29, 2025 – PRISM MediaWire – BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami.
BioStem Announces Notice of Allowance for Three New U.S. Patent Applications
Expanding patent portfolio reinforces the Company's commitment to wound care innovation, with 55 issued patents and 52 pending applications POMPANO BEACH, Fla., May 28, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist
Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future POMPANO BEACH, Fla., May 22, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies, Inc. (BSEM) Q1 2025 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Adam Holdsworth - Director-Investor Relations Jason Matuszewski - Chief Executive Officer Mike Fortunato - Chief Financial Officer Conference Call Participants Bruce Jackson - The Benchmark Company Erik Voss - Mission Vertical Operator Thank you for standing by. My name is Stan and I'll be your conference operator today.
BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results
POMPANO BEACH, FL, May 12, 2025 – PRISM MediaWire – BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics, today reported preliminary financial results for the first quarter ended March 31, 2025.
BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting
Company to co-exhibit with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three accepted scientific posters will feature BioStem's advanced allograft portfolio POMPANO BEACH, Fla., May 1, 2025 – PRiSM MediaWire – BioStem Technologies, Inc.
